NEW YORK, Aug 22 – Galapagos Genomics is collaborating with Vertex Pharmaceuticals to identify the function of various proteins, the company announced Wednesday.

Galapagos, a privately held company based in Mechelen, Belgium, will provide Vertex with recombinant adenoviruses via its PhenoSelect expression platform. Vertex plans to use the information for characterization of protein activity within targeted biological pathways.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.